Aktionärsstruktur

Inhaber in %
Freefloat 90,46
Basilea Pharmaceutica AG 9,55
Black Creek Investment Management, Inc. 4,97
Credit Suisse Asset Management (Schweiz) AG 3,25
The Vanguard Group, Inc. 2,47
BlackRock Fund Advisors 1,45
Zürcher Kantonalbank (Investment Management) 1,25
Norges Bank Investment Management 0,92
UBS AG (Investment Management) 0,87
Deka Investment GmbH 0,54
St. Galler Kantonalbank AG (Private Banking) 0,52
Apo Asset Management GmbH 0,45
Medical Strategy GmbH 0,35
Oddo BHF Asset Management SAS 0,35
Hottinger Capital Corp. 0,34

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2014 2015 2016 2017 2018
Personal am Ende des Jahres 230 250 240 228 227
Umsatz pro Mitarbeiter in Mio. EUR 0,18 0,21 0,27 0,45 0,58

Bilanz (in Mio. EUR) - Aktiva

2014 2015 2016 2017 2018
Summe Umlaufvermögen 244 385 268 292 274
Summe Anlagevermögen 58 210 160 155 130
Summe Aktiva 257 399 328 351 282

Bilanz (in Mio. EUR) - Passiva

2014 2015 2016 2017 2018
Gesamtverschuldung/ -verbindlichkeiten 0 195 195 196 196
Summe Fremdkapital 200 384 363 393 348
Summe Eigenkapital 58 15 -35 -41 -67
Summe Passiva 257 399 328 351 282

Adresse

Grenzacherstrasse 487, 4058 Basel
Telefon 41616061111
Fax 41616061112
Internet http://www.basilea.com

Management

Adesh Kaul EMBA
Chief Financial Officer
Alf Gunnar Martin Nicklasson, PhD
Independent Non-Executive Director
Damian Heller, MBA
Secretary & General Counsel
David Veitch
Chief Executive Officer
Domenico Scala, PhD
Chairman
Gerrit Hauck, PhD
Chief Technology Officer
Laurenz Kellenberger, PhD
Chief Scientific Officer
Marc Engelhardt MD, PhD
Chief Medical Officer
Nicole M. Onetto, MD
Non-Executive Director
Peer Nils Schröder, PhD
Head-Communications, Public & Investor Relations
Ronald Scott
Director
Steven D. Skolsky
Independent Non-Executive Director
Thomas Werner, PhD
Vice­-Chairman
Ursula Eberhardt
Head-Global Human Resources